Jung Goo-Young, Na Young-Eun, Park Mork-Soon, Park Chang-Sik, Myung Pyung-Keun
College of Pharmacy, Chungnam National University, Daejeon, 305-764, Korea.
Arch Pharm Res. 2009 Mar;32(3):359-65. doi: 10.1007/s12272-009-1308-9. Epub 2009 Apr 23.
The objective of this study was to investigate the potential of various formulation strategies to achieve sustained release of the peptide, from injectable poly(D,L-lactide-co-glycolide) (PLGA) and d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) microparticles. The microparticles were prepared by a solvent evaporation method. Peptide loaded PLGA microparticles exhibited a pronounced initial burst release (22.3% in 1 day) and lag phase in phosphate buffer of pH 7.0. In contrast, blending of 5.0% TPGS (8.6% release in 1 day) or 10.0% TPGS (5.5% release in 1 day) in PLGA microparticles reduced initial burst release and the lag-phase time. Incorporation of TPGS in PLGA microparticles further increased drug release, attributable to improved drug encapsulation, increased particle size, and exempt of pores. PLGA+ 10.0% TPGS composite microparticles exhibited the most desirable drug release among all the formulations tested, and demonstrated triphasic release after minimal initial burst.
本研究的目的是研究各种制剂策略从可注射的聚(D,L-丙交酯-共-乙交酯)(PLGA)和d-α-生育酚聚乙二醇1000琥珀酸酯(TPGS)微粒中实现肽持续释放的潜力。微粒通过溶剂蒸发法制备。载有肽的PLGA微粒在pH 7.0的磷酸盐缓冲液中表现出明显的初始突释(1天内释放22.3%)和延迟期。相比之下,在PLGA微粒中混合5.0% TPGS(1天内释放8.6%)或10.0% TPGS(1天内释放5.5%)可减少初始突释和延迟期时间。在PLGA微粒中加入TPGS进一步增加了药物释放,这归因于药物包封的改善、粒径的增加和孔隙的消除。在所有测试制剂中,PLGA + 10.0% TPGS复合微粒表现出最理想的药物释放,并在最小初始突释后呈现三相释放。